The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.
The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.
In this interview, Estelamari Rodriguez, MD, MPH, discusses the challenges and advancements in non-small cell lung cancer (NSCLC) care, including strategies for managing uncommon EGFR mutations, the potential of antibody-drug conjugates,...
In this interview, Estelamari Rodriguez, MD, MPH, discusses the challenges and advancements in non-small cell lung cancer (NSCLC) care, including strategies for managing uncommon EGFR mutations, the potential of antibody-drug conjugates,...
In this interview, Don S. Dizon, MD, discusses the need to address research gaps, integrate quality-of-life and psychosocial considerations, and improve care pathways to optimize outcomes for endometrial cancer patients.
In this interview, Don S. Dizon, MD, discusses the need to address research gaps, integrate quality-of-life and psychosocial considerations, and improve care pathways to optimize outcomes for endometrial cancer patients.
John M. Burke, MD, Rocky Mountain Cancer Centers, provides an overview of his study that examined the barriers providers face in initiating venetoclax-based treatment for patients with chronic lymphocytic leukemia (CLL).
John M. Burke, MD, Rocky Mountain Cancer Centers, provides an overview of his study that examined the barriers providers face in initiating venetoclax-based treatment for patients with chronic lymphocytic leukemia (CLL).
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Despite research advancements, racial and ethnic inequities continue to occur in cancer clinical trial participation, exacerbating disparities in access to investigational therapies. A recent study published in JNCI Cancer Spectrum explored...
Despite research advancements, racial and ethnic inequities continue to occur in cancer clinical trial participation, exacerbating disparities in access to investigational therapies. A recent study published in JNCI Cancer Spectrum explored...